Share on facebook
Share on twitter
Share on linkedin
Share on email

COVAXX Announces Initiation of Phase 2 Clinical Trials in Taiwan of UB-612 Vaccine Candidate against COVID-19

DALLAS, TX (Feb. 2, 2021) – COVAXX, a U.S. biotechnology company and subsidiary of United Biomedical, Inc. (UBI), has announced that the Taiwan Ministry of Health and Welfare on January 29, granted conditional approval to begin Phase 2 trials of UB-612, its vaccine candidate to address the pandemic caused by SARS-CoV-2. COVAXX is developing world’s first multitope peptide-based vaccine against COVID-19, using its high precision, commercially proven and scalable vaccine platform.